ESR1 and breast cancer: The main indication for an adjuvant treatment of breast cancer with anti-estrogens is the immunohistochemical identification of estrogen receptor (ER)-positive tumor cells that was suggested in 1987 [3] and has since evolved into a standardized diagnostic procedure.